Form 4: Alto Neuroscience Director Acquires Stock Options

Alto Neuroscience, Inc. reports that Director York Gwill was granted stock options on May 12, 2026, as part of the company's Non-Employee Director Compensation Policy.

Summary

• York Gwill, a Director at Alto Neuroscience, Inc., was granted 10,958 stock options on May 12, 2026.
• These options have an exercise price of $24.63 and an expiration date of May 11, 2036.
• The underlying securities are 10,958 shares of Common Stock.
• The options are subject to vesting conditions, including continuous service through the one-year anniversary of the grant date or the Issuer's next Annual Meeting.
• This grant was made under the Issuer's Non-Employee Director Compensation Policy, meaning no direct payment was made for the options.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral filing, as it represents a standard director compensation event rather than a significant financial or strategic development.

Positives

• Director compensation through stock options aligns the interests of management with shareholders.
• The grant of options indicates continued confidence in the company's future prospects by a board member.

Negatives

• The exercise price of $24.63 suggests that the stock price needs to appreciate significantly for these options to be in-the-money.
• Vesting conditions mean the director does not immediately own the underlying shares, and their ultimate benefit is contingent on continued service and company performance.

Risks

• The value of the stock options is subject to market volatility and the company's future performance.
• If the company's stock price does not exceed the exercise price of $24.63, the options will expire worthless.
• The vesting schedule introduces a risk of forfeiture if the reporting person's service is terminated before the vesting date.

Future Outlook

The future outlook for the stock options is dependent on the company's stock performance relative to the $24.63 exercise price and the reporting person's continued service to meet vesting requirements.

Industry Context

StockSavvy.ai notes that the issuance of stock options to directors is a common practice in the biotechnology and pharmaceutical sectors, including companies like Alto Neuroscience, to attract and retain experienced leadership and align their incentives with long-term shareholder value.

Corporate Governance

Related Party Transactions

• The grant of stock options to Director York Gwill is a related party transaction, as it involves compensation to a key insider.

Stakeholder Impact

• Shareholders: The grant of options aligns director incentives with shareholder value creation, but the ultimate impact depends on stock performance.
• Employees: This filing does not directly impact employees, but it reflects the company's compensation structure for its board.
• Management: The options provide a potential future financial benefit to the director, contingent on performance and service.

Next Steps

• The reporting person must maintain continuous service to satisfy vesting conditions for the stock options.
• The company will continue to operate under its Non-Employee Director Compensation Policy for future grants.

Key Dates

Keywords

Alto Neuroscience, ANRO, Form 4, Stock Options, Director Compensation, Beneficial Ownership, Securities Exchange Act, SEC Filing